Clive R. Wood, PhD is currently responsible for research in Inflammation, Oncology, Cardiometabolic Diseases and Central Nervous System Diseases at Boehringer with sites in Europe, USA and Asia.
Clive joined BI in 2014 and has built a globally integrated organization focused on scientific excellence and external innovation for unmet patient needs.
Before BI, Clive served as head of biologics research, process development and clinical manufacturing at Bayer HealthCare (2009-2014) and Chief Scientific Officer at Dyax Corp (2003-2009). Prior to Dyax, Clive was a Senior Scientist at Genetics Institute, Inc. and Scientist at Celltech Ltd., UK.
Clive’s personal scientific accomplishments have focused on antibody therapeutics and cytokines in oncology and inflammation. This includes his foundational discovery of the PD-1: PD-L1/PD-L2 pathway. He is notably a co-inventor of the core patents that relate to the treatment of cancer with antibodies against PD-1 and its ligands.
His educational contributions have included serving as Adjunct Professor, Dept. of Pharmacology, Boston University School of Medicine and founding a joint graduate training program between Genetics Institute (now Pfizer) and Boston University.
Clive was born and educated in the UK (BSc, PhD Biochemistry, Imperial College London).